Zhi-Hong Yang1, Marcelo Amar2, Alexander V Sorokin2, James Troendle3, Amber B Courville4, Maureen Sampson5, Martin P Playford6, Shanna Yang4, Michael Stagliano2, Clarence Ling5, Kwame Donkor2, Robert D Shamburek2, Nehal N Mehta6, Alan T Remaley2. 1. Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA. Electronic address: zhihong.yang@nih.gov. 2. Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA. 3. Office of Biostatistics Research, Division of Cardiovascular Sciences, NHLBI, NIH, Bethesda, MD, USA. 4. Clinical Center, Nutrition Department, NIH, Bethesda, MD, USA. 5. Clinical Center, Department of Laboratory Medicine, NIH, Bethesda, MD, USA. 6. Section of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch, NHLBI, NIH, Bethesda, MD, USA.
Abstract
BACKGROUND: Fish oil enriched in omega-11 long-chainmonounsaturated fatty acids (LCMUFAs; C20:1 and C22:1 isomers combined) have shown lipid-lowering and atheroprotective effects in animal models. OBJECTIVE: To perform a first-in-human trial of LCMUFA-rich saury fish oil supplementation to test its safety and possible effect on plasma lipids. METHODS: A double-blind, randomized, crossover clinical trial was carried out in 30 healthy normolipidemic adults (BMI <25 kg/m2; mean TG, 84 mg/dL). Treatment periods of 8 weeks were separated by an 8-week washout period. Subjects were randomized to receive either 12 g of saury oil (3.5 g of LCMUFA and 3.4 g of omega-3 FAs) or identical capsules with control oil (a mixture of sardine and olive oil; 4.9 g of shorter-chain MUFA oleate and 3 g of omega-3 FAs). RESULTS:Saury oil supplementation was safe and resulted in LDL particle counts 12% lower than control oil (P < .001). Saury oil also had a minor effect on increasing HDL particle size (9.8 nm vs 9.7 nm; P < .05) based on a linear mixed effect model. In contrast, control oil, but not saury oil, increased LDL-C by 7.5% compared with baseline (P < .05). Saury oil had similar effects compared with control oil on lowering plasma TG levels, VLDL, and TG-rich lipoprotein particle counts (by ∼16%, 25%, and 35%, respectively; P < .05), and increasing HDL-C and cholesterol efflux capacity (by ∼6% and 8%, respectively; P < .05) compared with baseline. CONCLUSION:Saury oil supplementation is well tolerated and has beneficial effects on several cardiovascular parameters, such as LDL particle counts, HDL particle size, and plasma TG levels. Published by Elsevier Inc.
RCT Entities:
BACKGROUND:Fish oil enriched in omega-11 long-chain monounsaturated fatty acids (LCMUFAs; C20:1 and C22:1 isomers combined) have shown lipid-lowering and atheroprotective effects in animal models. OBJECTIVE: To perform a first-in-human trial of LCMUFA-rich sauryfish oil supplementation to test its safety and possible effect on plasma lipids. METHODS: A double-blind, randomized, crossover clinical trial was carried out in 30 healthy normolipidemic adults (BMI <25 kg/m2; mean TG, 84 mg/dL). Treatment periods of 8 weeks were separated by an 8-week washout period. Subjects were randomized to receive either 12 g of sauryoil (3.5 g of LCMUFA and 3.4 g of omega-3 FAs) or identical capsules with control oil (a mixture of sardine and oliveoil; 4.9 g of shorter-chain MUFA oleate and 3 g of omega-3 FAs). RESULTS:Sauryoil supplementation was safe and resulted in LDL particle counts 12% lower than control oil (P < .001). Sauryoil also had a minor effect on increasing HDL particle size (9.8 nm vs 9.7 nm; P < .05) based on a linear mixed effect model. In contrast, control oil, but not sauryoil, increased LDL-C by 7.5% compared with baseline (P < .05). Sauryoil had similar effects compared with control oil on lowering plasma TG levels, VLDL, and TG-rich lipoprotein particle counts (by ∼16%, 25%, and 35%, respectively; P < .05), and increasing HDL-C and cholesterol efflux capacity (by ∼6% and 8%, respectively; P < .05) compared with baseline. CONCLUSION:Sauryoil supplementation is well tolerated and has beneficial effects on several cardiovascular parameters, such as LDL particle counts, HDL particle size, and plasma TG levels. Published by Elsevier Inc.
Authors: W Greg Miller; Gary L Myers; Ikunosuke Sakurabayashi; Lorin M Bachmann; Samuel P Caudill; Andrzej Dziekonski; Selvin Edwards; Mary M Kimberly; William J Korzun; Elizabeth T Leary; Katsuyuki Nakajima; Masakazu Nakamura; Göran Nilsson; Robert D Shamburek; George W Vetrovec; G Russell Warnick; Alan T Remaley Journal: Clin Chem Date: 2010-04-08 Impact factor: 8.327
Authors: Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet Journal: Circulation Date: 2012-04-17 Impact factor: 29.690
Authors: Devashish Kothapalli; Shu-Lin Liu; Yong Ho Bae; James Monslow; Tina Xu; Elizabeth A Hawthorne; Fitzroy J Byfield; Paola Castagnino; Shilpa Rao; Daniel J Rader; Ellen Puré; Michael C Phillips; Sissel Lund-Katz; Paul A Janmey; Richard K Assoian Journal: Cell Rep Date: 2012-10-25 Impact factor: 9.423
Authors: Theingi Aung; Jim Halsey; Daan Kromhout; Hertzel C Gerstein; Roberto Marchioli; Luigi Tavazzi; Johanna M Geleijnse; Bernhard Rauch; Andrew Ness; Pilar Galan; Emily Y Chew; Jackie Bosch; Rory Collins; Sarah Lewington; Jane Armitage; Robert Clarke Journal: JAMA Cardiol Date: 2018-03-01 Impact factor: 14.676
Authors: Karla Paulina Luna-Castillo; Sophia Lin; José Francisco Muñoz-Valle; Barbara Vizmanos; Andres López-Quintero; Fabiola Márquez-Sandoval Journal: Nutrients Date: 2021-04-01 Impact factor: 5.717